TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25805811

Group type: EXPERIMENTAL
Intervention: Vosaroxin
Number of subjects: 208

Group type: COMPARATOR
Intervention: Low-dose Ara-C (LDAC)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Vosaroxin + LDAC
Number of subjects: 208
Study: 24722949

Group type: EXPERIMENTAL
Intervention: Average static respiratory compliance over the first 14 days after diagnosis
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Average static respiratory compliance at day 14
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Initial static respiratory compliance obtained within the first day after ARDS diagnosis
Number of subjects: 82
Study: 23024438

Group type: EXPERIMENTAL
Intervention: 2.5 mg melatonin nightly for 3 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19646075

Group type: EXPERIMENTAL
Intervention: Pharmacists' interventions in repeat prescribing, including a pharmacist's interview and annual medication data transfer to prescribing physician.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal repeat prescribing process (comparison group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacists' interventions in repeat prescribing.
Number of subjects: 0
Study: 17544597

Group type: EXPERIMENTAL
Intervention: (125)I
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: (103)Pd
Number of subjects: 164

Group type: COMPARATOR
Intervention: Neoadjuvant androgen deprivation therapy
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Age <65 years
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Age >=65 years
Number of subjects: 164
Study: 14712425

Group type: EXPERIMENTAL
Intervention: Worsened renal function (creatinine level increase > or = 0.3 mg/dL) during HERS
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Baseline creatinine levels from HERS
Number of subjects: 2763
Study: 11252010

Group type: EXPERIMENTAL
Intervention: New combination regimens in phase II cancer clinical trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proposed adjustment method for standard therapy outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Median survival estimation in confirmatory phase II trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjustment method based on bootstrap resampling technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation study
Number of subjects: 0
Study: 9228378

Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV) during sleep
Number of subjects: 21

Group type: COMPARATOR
Intervention: Oxygen therapy
Number of subjects: 21
Study: 8496534

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy administered to 55 patients 3.2 +/- 2.1 hours after the onset of symptoms.
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (49 patients) without thrombolytic therapy.
Number of subjects: 104
Study: 3573270

Group type: EXPERIMENTAL
Intervention: 400 mL of autologous, previously frozen deglycerolized RBCs
Number of subjects: 6

Group type: COMPARATOR
Intervention: 100 mL of saline solution
Number of subjects: 6
Study: 29596102

Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine 75 µg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 75 µg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 64
Study: 27912953

Group type: EXPERIMENTAL
Intervention: Herbal mouthwash (Matricaria recutita and Mentha piperita), used three times daily for at least 30 seconds, starting one week before HSCT.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo mouthwash, used three times daily for at least 30 seconds, starting one week before HSCT.
Number of subjects: 60
Study: 25226824

Group type: EXPERIMENTAL
Intervention: Low alcohol consumption (1 drink or 15g/day) for 8 weeks
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption (2 drinks or 30g/day) for 8 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: No alcohol consumption
Number of subjects: 51
Study: 23633746

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention with a behavioral weight loss program
Number of subjects: 264

Group type: COMPARATOR
Intervention: Diabetes support and education
Number of subjects: 264
Study: 20677584

Group type: EXPERIMENTAL
Intervention: Electroacupuncture and pharmacologic analgesia (acupuncture)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pharmacologic analgesia alone (control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 18301905

Group type: EXPERIMENTAL
Intervention: BTX-A injection
Number of subjects: 74

Group type: COMPARATOR
Intervention: Normal saline injection (control)
Number of subjects: 74
Study: 12585101

Group type: EXPERIMENTAL
Intervention: Xuesaitong (XST) soft capsule
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9817163

Group type: EXPERIMENTAL
Intervention: High molecular weight agents in powder form (two concentrations administered: half and double the one that caused a 20% fall in FEV1)
Number of subjects: 9
Study: 7714943

Group type: EXPERIMENTAL
Intervention: ampicillin/sulbactam (1 g ampicillin/0.5 g sulbactam) plus 1 g probenecid orally
Number of subjects: 330

Group type: COMPARATOR
Intervention: ceftriaxone (250 mg)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: ampicillin/sulbactam
Number of subjects: 330

Group type: COMPARATOR
Intervention: ceftriaxone
Number of subjects: 330
Study: 2720576

Group type: EXPERIMENTAL
Intervention: Controlled-release morphine sulfate tablets (MS Contin) given every 12 hours
Number of subjects: 23

Group type: COMPARATOR
Intervention: Oral morphine sulfate solution (MSS) given every 4 hours
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Controlled-release morphine sulfate tablets (MS Contin) given every 8 hours
Number of subjects: 23
Study: 311410

Group type: EXPERIMENTAL
Intervention: Nystatin
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Natamycin
Number of subjects: 56

Group type: COMPARATOR
Intervention: No anticandidal prophylaxis (Control)
Number of subjects: 56
Study: 31283676

Group type: EXPERIMENTAL
Intervention: Graphical presentations of information regarding transplant rates
Number of subjects: 975
Study: 30829836

Group type: EXPERIMENTAL
Intervention: Health-care provider letters
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Postcard mailings
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Facebook posts
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Family and friends referrals
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Newspaper or television
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Digital ads
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Digital ads and postcard mailings
Number of subjects: 276
Study: 28355890

Group type: EXPERIMENTAL
Intervention: Expressive writing about thoughts and feelings specific to lymphedema and its treatment
Number of subjects: 107

Group type: COMPARATOR
Intervention: Writing about daily activities (control)
Number of subjects: 107
Study: 25583588

Group type: EXPERIMENTAL
Intervention: Ai Chi aquatic therapy programme
Number of subjects: 20
Study: 23338547

Group type: EXPERIMENTAL
Intervention: Individualized and supervised exercise program for pelvic floor muscles (PFM), 8 weeks, twice a week
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control Group (no exercise recommendations)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Assessment methods: digital vaginal palpation and perineometer
Number of subjects: 23
Study: 21839816

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1200 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 19143690

Group type: EXPERIMENTAL
Intervention: Tramadol 1 mg.kg(‐1)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Tramadol 2 mg.kg(‐1)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Tramadol 3 mg.kg(‐1)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Pethidine 0.5 mg.kg(‐1)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 165
Study: 17288323

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond with Clearfil ST resin composite (SE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single Bond with A110 resin composite (SB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fuji II LC (FJ)
Number of subjects: 20
Study: 15481276

Group type: EXPERIMENTAL
Intervention: R-salbutamol (0.63 mg inhaled three times daily for 1 week)
Number of subjects: 26

Group type: COMPARATOR
Intervention: R,S-salbutamol (1.25 mg inhaled three times daily for 1 week)
Number of subjects: 26
Study: 11915302

Group type: EXPERIMENTAL
Intervention: 0.5% phosphorylated chitosan mouth rinse
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo rinsing
Number of subjects: 3
Study: 9272411

Group type: EXPERIMENTAL
Intervention: Foscarnet administered as an infusion twice daily (BID)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Foscarnet administered as an infusion thrice daily (TID)
Number of subjects: 12
Study: 7935029

Group type: EXPERIMENTAL
Intervention: Oral conjugated oestrogens (oCE) + dydrogesterone (DYDR)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Oral conjugated oestrogens (oCE) + norethisterone acetate (NETA)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol (tdE2) + dydrogesterone (DYDR)
Number of subjects: 2
Study: 3286509

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (1,000 mg daily)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Norfloxacin (800 mg daily)
Number of subjects: 51
Study: 31336212

Group type: EXPERIMENTAL
Intervention: Twin Mix (1.8ml 2% lignocaine with 1:200,000 epinephrine and 1ml/4mg dexamethasone)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Modified Twin Mix (1.7ml of 4% articaine with 1:100,000 epinephrine and 1ml/4mg dexamethasone)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (1.8ml of 2% lignocaine with 1:200,000 adrenaline)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (1.7ml of 4% articaine with 1:100,000 adrenaline)
Number of subjects: 20
Study: 30784356

Group type: EXPERIMENTAL
Intervention: Tramadol or codeine
Number of subjects: 102
Study: 27362908

Group type: EXPERIMENTAL
Intervention: Diluted vasopressin solution (20 U in 400 ml normal saline)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Concentrated vasopressin solution (20 U in 60 ml normal saline)
Number of subjects: 152
Study: 25464058

Group type: EXPERIMENTAL
Intervention: Participants who exerted self-control before a taste test of unhealthy food
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (participants who did not exert self-control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-perceived successful weight regulators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived unsuccessful self-regulators
Number of subjects: 0
Study: 23775057

Group type: EXPERIMENTAL
Intervention: Ziprasidone 320 mg/d
Number of subjects: 75

Group type: COMPARATOR
Intervention: Ziprasidone 160 mg/d
Number of subjects: 75
Study: 21911976

Group type: EXPERIMENTAL
Intervention: H. pylori treatment group (amoxicillin, clarithromycin, omeprazole for 2 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 40
Study: 19934241

Group type: EXPERIMENTAL
Intervention: One tooth bleaching (35% hydrogen peroxide enabled by LEDs)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Two tooth bleachings interspersed by aging
Number of subjects: 72

Group type: COMPARATOR
Intervention: No bleaching (control group)
Number of subjects: 72
Study: 17214750

Group type: EXPERIMENTAL
Intervention: Aquatic exercise (12-week program)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-exercise control condition
Number of subjects: 38
Study: 15562881

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 52
Study: 11573520

Group type: EXPERIMENTAL
Intervention: Nicorandil (HD group: 0.08 mg kg(‐1) bolus and 0.08 mg kg(‐1) h(‐1) continuous infusion)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Nicorandil (LD group: 0.04 mg kg(‐1) bolus and 0.04 mg kg(‐1) h(‐1) continuous infusion)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 248
Study: 10452064

Group type: EXPERIMENTAL
Intervention: Escharectomy during burn shock stage
Number of subjects: 60
Study: 7934434

Group type: EXPERIMENTAL
Intervention: Unwashed breast
Number of subjects: 30

Group type: COMPARATOR
Intervention: Washed breast
Number of subjects: 30
Study: 2896870

Group type: EXPERIMENTAL
Intervention: Serum P3NP levels
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Cox multivariate analysis of serum P3NP
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Correlations with serum P3NP
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Raised P3NP levels
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Serum P3NP
Number of subjects: 63
Study: 31973702

Group type: EXPERIMENTAL
Intervention: Antianxiety Granule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28819993

Group type: EXPERIMENTAL
Intervention: Lactobacillus helveticus-fermented milk drink (190 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo drink (equivalent amount)
Number of subjects: 0
Study: 28248054

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (50 mg of testosterone as a 1% topical gel Androgel for 12 weeks postoperatively)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no testosterone replacement therapy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (50 mg of testosterone as a 1% topical gel Androgel)
Number of subjects: 60
Study: 25557125

Group type: EXPERIMENTAL
Intervention: propofol‐remifentanil (group PR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: propofol‐ketamine (group PK)
Number of subjects: 50
Study: 24304332

Group type: EXPERIMENTAL
Intervention: Verapamil penile injections (12 total injections for six months and subsequently every month for twelve months: total 24 injections) + Iontophoresis with Verapamil/daily + blueberries 160mg/daily + propolis 600mg/daily + Vitamin E 600mg/daily + topical Diclofenac/daily
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Verapamil penile injections (and associated treatments)
Number of subjects: 82
Study: 19802506

Group type: EXPERIMENTAL
Intervention: Weight training exercises plus risedronate, calcium, and vitamin D
Number of subjects: 223

Group type: COMPARATOR
Intervention: Risedronate, calcium, and vitamin D only
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Adherence to exercise (≥50%)
Number of subjects: 223
Study: 18157071

Group type: EXPERIMENTAL
Intervention: Valacyclovir 1 g daily for 60 days
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 16877730

Group type: COMPARATOR
Intervention: Letrozole (2.5 mg daily for 6 months)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Letrozole plus oral cyclophosphamide (50 mg daily for 6 months)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Letrozole plus oral cyclophosphamide
Number of subjects: 114
Study: 12940940

Group type: EXPERIMENTAL
Intervention: Glucose supplementation during exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (no glucose supplementation) during exercise
Number of subjects: 6
Study: 10711900

Group type: EXPERIMENTAL
Intervention: Topical aqueous suppressants
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (no topical aqueous suppressants)
Number of subjects: 41
Study: 9010961

Group type: EXPERIMENTAL
Intervention: human corticotropin releasing factor (hCRF)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: hCRF/naloxone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: combined multifaceted 5-min stress test
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: novelty-related anticipation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: age-related differences in AVP levels
Number of subjects: 10
Study: 1390121

Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen (0.6 mg/kg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 5-methoxypsoralen (1.2 mg/kg)
Number of subjects: 39
Study: 4005392

Group type: EXPERIMENTAL
Intervention: Sustained-release tablets containing 40 mg isosorbide dinitrate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference standard-release tablets containing 20 mg isosorbide dinitrate
Number of subjects: 12
Study: 31545577

Group type: EXPERIMENTAL
Intervention: PEEP of 15 cmH2O
Number of subjects: 66

Group type: COMPARATOR
Intervention: PEEP of 10 cmH2O
Number of subjects: 66

Group type: COMPARATOR
Intervention: PEEP of 12 cmH2O
Number of subjects: 66
Study: 30497497

Group type: EXPERIMENTAL
Intervention: Groundnut production constraints assessment through participatory rural appraisal approach
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Farmers' trait preferences assessment
Number of subjects: 180
Study: 27243900

Group type: EXPERIMENTAL
Intervention: PrEP adherence (pill count coverage)
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: PrEP adherence (plasma tenofovir levels)
Number of subjects: 1785
Study: 24737199

Group type: EXPERIMENTAL
Intervention: Highest tertile of 1,25(OH)2D
Number of subjects: 1151

Group type: COMPARATOR
Intervention: Second tertile of 1,25(OH)2D
Number of subjects: 1151

Group type: COMPARATOR
Intervention: Third tertile of 1,25(OH)2D
Number of subjects: 1151
Study: 21831487

Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated 0.5% ropivacaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine with 1:200,000 adrenaline
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2% lignocaine with 1:100,000 adrenaline
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ropivacaine with adrenaline
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lignocaine with adrenaline
Number of subjects: 40

Group type: COMPARATOR
Intervention: All groups tested
Number of subjects: 40
Study: 20929609

Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone Propionate (SFC) 50 μg/100 μg b.i.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fluticasone Propionate (FP) 200 μg b.i.d.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone Propionate (SFC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fluticasone Propionate (FP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone Propionate (SFC) and Fluticasone Propionate (FP)
Number of subjects: 24
Study: 18621797

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 50

Group type: COMPARATOR
Intervention: 8‐0 Vicryl sutures
Number of subjects: 50
Study: 15823204

Group type: EXPERIMENTAL
Intervention: Executive Walk Rounds (EWRs)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Control group (no EWR participation)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: EWRs
Number of subjects: 283
Study: 12821239

Group type: EXPERIMENTAL
Intervention: rNAPc2 at 3.5 microg/kg
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: rNAPc2 at 5.0 microg/kg
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: rNAPc2 at 7.5 microg/kg
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: rNAPc2 at 10.0 microg/kg
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 10620633

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8656173

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study: 1386374

Group type: EXPERIMENTAL
Intervention: GnRHa with norethindrone 5 then 10 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: GnRHa alone (placebo group)
Number of subjects: 20
Study: 6693601

Group type: EXPERIMENTAL
Intervention: Self-application of topical medication
Number of subjects: 29

Group type: COMPARATOR
Intervention: Application by a trained attendant
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Self-application of fluorescent sunscreen
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cream vs ointment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Alcoholic liquid vs creamy liquid
Number of subjects: 29
Study: 31627089

Group type: EXPERIMENTAL
Intervention: Triple fixed-dose combination (TFC) therapy of perindopril/indapamide/amlodipine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Triple free combination therapy (FCT) including ACEI/diuretic/CCB
Number of subjects: 92
Study: 29357380

Group type: EXPERIMENTAL
Intervention: Peer-led structured patient education (n = 76)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Conventional care alone (n = 75)
Number of subjects: 151
Study: 26155765

Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg, twice daily during 12 weeks of chemotherapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo, twice daily during 12 weeks of chemotherapy
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 24646102

Group type: EXPERIMENTAL
Intervention: 4000 IU vitamin D3 daily (group B)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Routine care (200 mg ferrous sulfate and 600 mg calcium daily, group A)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Routine care (group A)
Number of subjects: 193
Study: 23302671

Group type: EXPERIMENTAL
Intervention: Policosanol, 20 mg/d, n = 36
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo, two tablets/d, n = 36
Number of subjects: 72
Study: 19913351

Group type: EXPERIMENTAL
Intervention: FL cystoscopy
Number of subjects: 300

Group type: COMPARATOR
Intervention: WL cystoscopy
Number of subjects: 300
Study: 17697309

Group type: EXPERIMENTAL
Intervention: G-TIVA-TEA (Total Intravenous Anesthesia with Thoracic Epidural Anaesthesia)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: G-TIVA (Total Intravenous Anesthesia without Thoracic Epidural Anaesthesia)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: G-ISO-TEA (Isoflurane Anaesthesia with Thoracic Epidural Anaesthesia)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: G-ISO (Isoflurane Anaesthesia without Thoracic Epidural Anaesthesia)
Number of subjects: 100